SOURCE-LINKED STUDY SUMMARY
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
Abstract summarizedQuality not appraised
- What was studied
- Randomized trial comparing oral semaglutide with placebo alongside standard care for cardiovascular death, nonfatal heart attack or stroke.
- Who / model studied
- 9650 adults aged 50 or older with type 2 diabetes and cardiovascular disease, chronic kidney disease or both; median follow-up was 49.5 months.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The primary cardiovascular outcome occurred in 12.0% versus 13.8%. Confirmatory secondary outcomes, including kidney disease events, did not differ significantly. Serious adverse events occurred in 47.9% versus 50.3%, and digestive disorders in 5.0% versus 4.4%.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2501006